Recombinant Human ADAM8 protein (rFc Tag)

Species

Human

Purity

>70 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2912



Product Information

Purity >70 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human ADAM8 protein Ile17-Pro497 (Accession# P78325-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 101
Accession P78325-1
PredictedSize 78.5 kDa
SDS-PAGE 68-75 kDa and 85-100 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

ADAM8 (A Disintegrin and Metalloproteinase 8) is also known as CD156a (cluster of differentiation 156a), a transmembrane glycoprotein belonging to the ADAM family of metalloproteinase-disintegrins. Under physiological conditions, its expression is relatively low and dispensable. However, its expression is potently induced by a variety of inflammatory stimuli, including cytokines (e.g., TNF-α, IL-1β, IFN-γ), lipopolysaccharide (LPS), and hypoxic conditions. ADAM8 is significantly expressed in key immune cells within inflammatory and tumor microenvironments. It is found in neutrophils), macrophages, and natural killer (NK) cells. In neutrophils, it is crucial for migration and transmigration. ADAM8 is also highly overexpressed in some aggressive cancers, including pancreatic ductal adenocarcinoma (PDAC), high expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome.

References:

1.Kuo, Paul C et al. Cancers vol. 15,12 (2023). 2.Cuffaro, Doretta et al. ACS medicinal chemistry letters vol. 12,11 (2021): 1787-1793. 3.Zuo, Wenjie et al. Journal of advanced research vol. 73, (2025): 483-499. 4.Schlomann, Uwe et al. Nature communications vol. 6, (2015): 6175.

||
New chat

Able

正在加载,请稍候...